MedTrace Logo

Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184

NCT07636928 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-07-02

No results posted yet for this study

Summary

The purpose of the study is to assess the bioavailability, mass balance, pharmacokinetics, metabolism and excretion of radiolabeled (14C) VH4524184.

Conditions

  • HIV Infections

Interventions

DRUG

VH4524184

One dose of VH4524184 is administered to participants at time zero on Day 1 (Period 1).

DRUG

[14C]VH4524184 microdose

A radiolabelled microdose of \[14C\]VH4524184 is administered 2.5 hours after VH4524184 dose administration on Day 1 (Period1).

DRUG

[14C]VH4524184

One dose of radiolabelled \[14C\]VH4524184 is administered to participants at Day 15 (Period 2).

Sponsors & Collaborators

  • ViiV Healthcare

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-04
Primary Completion
2026-08-20
Completion
2026-08-20
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07636928 on ClinicalTrials.gov